Production (Stage)
Tenax Therapeutics, Inc.
TENX
$6.07
$0.020.33%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 125.76% | 35.57% | 19.70% | 3.16% | -8.21% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 153.91% | 136.76% | 108.67% | 58.10% | 7.39% |
| Operating Income | -153.91% | -136.76% | -108.67% | -58.10% | -7.39% |
| Income Before Tax | -139.64% | -128.27% | -107.01% | -57.58% | -3.80% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -139.64% | -128.27% | -107.01% | -57.58% | -3.80% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -139.64% | -128.27% | -107.01% | -57.58% | -3.80% |
| EBIT | -153.91% | -136.76% | -108.67% | -58.10% | -7.39% |
| EBITDA | -47.06% | -136.89% | -108.64% | -58.06% | -7.35% |
| EPS Basic | 89.91% | 84.16% | 86.98% | 92.37% | 94.79% |
| Normalized Basic EPS | 89.91% | 84.15% | 86.99% | 92.37% | 94.79% |
| EPS Diluted | 89.91% | 84.16% | 86.98% | 92.37% | 94.79% |
| Normalized Diluted EPS | 89.91% | 84.15% | 86.99% | 92.37% | 94.79% |
| Average Basic Shares Outstanding | 4,439.52% | 5,924.11% | 3,337.59% | 767.88% | 1,101.32% |
| Average Diluted Shares Outstanding | 4,439.52% | 5,924.11% | 3,337.59% | 767.88% | 1,101.32% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |